Kodiak Sciences (#KOD) surged after reporting positive Phase 3 DAYBREAK results for its wet age-related macular degeneration (AMD) programs. 🔹 Key Highlights 📈 #KOD: $52.48 | 62% UP in the reported market update. 📊 Float: 59.61M | Market Cap: $2.03B. 👁️ Zenkuda and tabirafusp-ted both met the primary endpoint. 🧪 Both treatments were non-inferior to aflibercept in visual acuity improvement. 🚀 Results add another positive Phase 3 readout for Kodiak's wet AMD programs. 📅 Zenkuda regulatory filing is planned for Q4 2026. 🔬 The filing is expected to be supported by data from five positive Phase 3 studies. 💡 Why It Matters The DAYBREAK results add important late-stage data to Kodiak's wet AMD development program. A planned Q4 2026 regulatory filing for Zenkuda represents the next major milestone for the company. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified